1 min read
Add as a preferred source on GoogleJ&J Says Second CAPLYTA Study Met Endpoints in Bipolar I Mania Trial
Study 452 tested adults with bipolar I disorder experiencing manic episodes, with or without mixed features.
Johnson & Johnson (J&J) said Nov. 10 that its second pivotal Phase 3 study of CAPLYTA met its primary and key secondary endpoints in adults with bipolar I disorder experiencing manic episodes, with or without mixed features.
The study, identified as Study 452, marks a second late-stage success for CAPLYTA in bipolar mania.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.